Skip to main content

Horizon Licenses Harvard Gene Editing IP

NEW YORK (GenomeWeb News) – Horizon Discovery announced today that it has licensed non-exclusive rights to Harvard University's intellectual property covering gene-editing technology.

The Cambridge, UK-based firm said the license covers the commercialization of products that utilize Harvard's CRISPR gene-editing technology for research use. CRISPR is an RNA-guided gene editing system that can introduce either a targeted double strand break or single strand nick in the genome of mammalian cells.

Horizon said that it will add the technology to its own Genesis gene-editing technologies platform, and added that it will soon launch a range of rAAV, CRISPR, and hybrid rAAV/CRISPR gene-editing kits and associated reagents.

"The introduction of a nick rather than a full double strand break offers advantages over other nuclease technologies when the goal of the project is to introduce a specific mutation rather than simply disrupting the gene," Eric Rhodes, CTO of Horizon Discovery, said in a statement. "By combining both CRISPR and ZFNs with our proprietary rAAV technology, Horizon is working to develop novel approaches that achieve levels of gene editing efficiency not previously seen when using a single approach alone."

Financial and other terms of the license were not disclosed.

Horizon recently licensed non-exclusive rights to use Sigma-Aldrich's zinc finger nuclease technology to develop cell-based products and provide commercial gene editing services.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.